The MHRA approved EURneffy, a needle-free adrenaline nasal spray for emergency anaphylaxis treatment in the UK on July 18, 2025. This innovative treatment is designed for adults and children weighing over 30 kg.
This approval marks a significant advancement in allergy treatment, offering a user-friendly alternative to traditional auto-injectors.
Introduction of EURneffy in the UK
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has officially approved EURneffy, the first needle-free adrenaline nasal spray designed for the emergency treatment of anaphylaxis. This approval, dated July 18, 2025, allows the use of EURneffy for both adults and children weighing more than 30 kg.
Developed by ARS Pharmaceuticals and commercialized by ALK-Abelló, EURneffy represents a significant shift in the approach to emergency allergy treatments in the UK.
Details of EURneffy’s Design and Usage
EURneffy is designed with a single-dose nozzle that delivers 2mg of epinephrine through nasal administration. This design eliminates the need for needles, making it an ideal option for individuals with needle phobia and for situations where quick administration is crucial.
The product is also shelf-stable, which offers an advantage over some traditional auto-injectors that require specific temperature conditions for storage.
Global Approval and Commercialization Strategy
Prior to its approval in the UK, EURneffy received approval from the U.S. FDA in October 2024 and from the European Commission in August 2024. These approvals are part of ARS Pharmaceuticals’ strategy to expand globally, partnering with companies like ALK-Abelló for commercialization rights in Europe and Canada.
This strategic partnership and successive approvals underscore the global trust and recognition of EURneffy’s potential in emergency allergy treatment.
Expert Opinions on EURneffy
Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, commented on the approval, emphasizing the balance between innovation and proven efficacy.
“Patient safety is our top priority, which is why we’re pleased to approve the first needle-free nasal spray formulation of adrenaline for the emergency treatment of anaphylaxis in the UK. Until now, adrenaline for self-administration has only been available via auto-injectors.”
His statement highlights the regulatory body’s commitment to integrating innovative solutions while ensuring they meet stringent safety standards.
Quick Facts About EURneffy’s Approval and Features
| Category | Detail |
|---|---|
| Approval Date | July 18, 2025 |
| Design | Single-dose nasal spray, 2mg epinephrine |
| Storage | Shelf-stable formulation |
| Global Approvals | Previously approved in the US and EU |
Expanding Access to Allergy Treatments: What It Means for Patients
The introduction of EURneffy is expected to significantly improve accessibility to emergency anaphylaxis treatment. Its needle-free design simplifies the administration process, potentially increasing adherence among those who are hesitant or unable to use traditional auto-injectors.
Moreover, the recommendation to carry two devices ensures that a backup is available in case a second dose is necessary, further enhancing patient safety and preparedness.
Reflections on Pharmaceutical Innovation
The approval of EURneffy reflects broader trends in pharmaceuticals, particularly the shift towards nasal drug delivery systems in emergency medical scenarios. This method not only addresses the challenges associated with injection-based technologies but also opens new avenues for drug administration in critical care.
This innovation is part of a larger movement within the industry to develop more patient-friendly and accessible treatment options for severe conditions like anaphylaxis.
Additional Reading
Sources: Gov.uk, ARS Pharma, Medicines and Healthcare products Regulatory Agency, and Anaphylaxis.org.uk.
Prepared by Ivan Alexander Golden, Founder of THX News™, an independent news organization delivering timely insights from global official sources. Combines AI-analyzed research with human-edited accuracy and context.
